-
AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline
•
US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant Roche’s (SWX: ROG) peptide discovery spinout, Nimble Therapeutics, in a deal initially valued at USD 200 million in cash. This strategic acquisition is aimed at strengthening AbbVie’s immunology product pipeline. Acquisition Highlights and Nimble’s Lead…
